Oral weight-loss drugs show promising results in trials by Novo Nordisk and Pfizer.

Novo Nordisk and Pfizer have released data showing that pills from the same class as Novo's weight loss drugs are as effective as injected medicines. Novo Nordisk's semaglutide pill helped overweight or obese adults lose weight comparable to what is seen with injected Wegovy, while Pfizer's oral compound resulted in weight loss similar to that of Novo's injected Ozempic. The enormous demand for weight-loss treatments could support up to 10 competing products with annual sales reaching up to $100 billion within a decade. Novo Nordisk expects to file for U.S. and European approval of the daily tablet this year, contingent on portfolio prioritizations and manufacturing capacity.